Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Hemogenyx Pharmaceuticals PLC (LSE:HEMO) Attracts Upside Interest as Cell Therapy Feasibility Work Expands Future Options

The company announced a feasibility agreement to test whether targeted lipid nanoparticles can deliver its CAR-encoding messenger RNA to human T cells. The work explores a possible route towards an in vivo therapy. This is a laboratory evaluation, while the existing early-stage clinical programme …

Ankur Sharma | 20 October 2026

ImmuPharma: Clinical Milestones and Funding Remain the Key Catalysts (LSE:IMM)

ImmuPharma remains a development-stage biotechnology story where investors monitor clinical progress, licensing opportunities, regulatory milestones and cash runway. No specific new announcement for 19 October was verified.

Ankur Sharma | 19 October 2026

ImmuPharma plc (LSE:IMM): What Could Drive the Next Move as Investors Track Key Milestones?

• Key focus: Clinical development priorities, licensing prospects and cash runway.

Ankur Sharma | 19 October 2026

IXICO and the AI Clinical-Trial Opportunity: What Investors Need to Watch (LSE:IXI)

IXICO plc operates in AI-enabled medical imaging analytics for neurological clinical trials.

Ankur Sharma | 19 October 2026

IXICO Outlook Hinges on Clinical-Trial Demand and Contract Conversion (LSE:IXI)

IXICO Plc (LSE:IXI) sits in the healthcare category, with exposure to digital analytics and imaging services for neurological clinical trials.

Ankur Sharma | 19 October 2026

Oxford BioDynamics Plc (LSE:OBD): What Could Drive the Next Move as Investors Track Key Milestones?

• Oxford BioDynamics Plc (LSE:OBD) is being assessed against its next operational and financial milestones.

Ankur Sharma | 19 October 2026

Proteome Sciences: Can Specialist Biomarker Work Deliver Repeat Revenue? (LSE:PRM)

Proteome Sciences plc (LSE:PRM) sits in the healthcare category, with exposure to proteomics services and biomarker research supporting drug development.

Ankur Sharma | 19 October 2026

Physiomics: Can Modelling Services Convert Into Repeat Client Work? (LSE:PYC)

Physiomics Plc (LSE:PYC) sits in the healthcare category, with exposure to mathematical modelling and simulation services for drug development.

Ankur Sharma | 19 October 2026

SkinBioTherapeutics: Can Microbiome Science Deliver Commercial Scale? (LSE:SBTX)

SkinBioTherapeutics plc operates in skin microbiome science and skin-health products.

Ankur Sharma | 19 October 2026

ValiRx: Can Scientific Progress Attract Commercial Partners? (LSE:VAL)

ValiRx PLC (LSE:VAL) sits in the healthcare category, with exposure to biotechnology research and early-stage therapeutic development.

Ankur Sharma | 19 October 2026
Support

Hi! How can we help you today?

Loading…